Emelianenko-Mitrione bout postponed due to American’s illnessSport February 19, 4:06
OSCE unable to identify perpetrators of cyber attacks against it - secretary generalWorld February 19, 4:02
Russian biathletes win gold in relay at 2017 IBU World Championships in AustriaSport February 18, 18:30
Putin signs decree on recognition of documents given to Donbass peopleRussian Politics & Diplomacy February 18, 17:26
Sberbank CEO says no repeat of crisis in the short termBusiness & Economy February 18, 17:24
Judging by certain statements at Munich Conference, "cold war" is still not over — LavrovRussian Politics & Diplomacy February 18, 15:19
Bout’s lawyers will challenge Court of Appeals’ decision in Supreme Court on February 21Russian Politics & Diplomacy February 18, 7:16
Turkish Minister reproaches NATO for not fulfilling obligations on its south-eastern flankWorld February 18, 7:12
Moody's upgrades outlook on Russia’s sovereign rating to stable from negativeBusiness & Economy February 18, 2:37
NOVOSIBIRSK, November 14 (Itar-Tass) - Scientists at Russia's SibEnzyme enterprise in the Siberian city of Novosibirsk have developed a brand new method to diagnose oncological diseases at very early stages, the company’s chief executive, Yevgeny Dubinin, told Itar-Tass at the international forum for technological development Technoprom.
The new method allows to detect cancer cells even if the sample under scrutiny (blood, phlegm, urine or smear) contains only few DNA molecules with abnormally methylated (abnormally working, ‘silent’ genes), according to Dubinin.
The company’s enzyme, whose patented technology detects methylated genes, is used as a tumor marker. Analysis is simple and reliable - carried out on standard equipment, in one vial and in three stages, it takes only about four hours.
“There is almost no early cancer diagnostic in Russia, while treating the disease when it is detected at the third and fourth stages yields little effect,” Dubinin said.
The new method will be indispensable for oncological centres, diagnostic laboratories, and other medical institutions, the director added. The estimated market volume is about 5.5 million examinations and 1.8 million for rare types of cancer.